Comment on Chandler et al. 23-Valent Pneumococcal Polysaccharide Vaccination Does Not Prevent Community-Acquired Pneumonia Hospitalizations Due to Vaccine-Type Streptococcus pneumoniae. Microorganisms 2022, 10, 560
Open Access
- 8 October 2022
- journal article
- editorial
- Published by MDPI AG in Microorganisms
- Vol. 10 (10) , 1987
Abstract
The 23-valent pneumococcal polysaccharide vaccine (PPSV23) targets 23 common serotypes and is recommended for use in adults in various countries to protect against pneumococcal infection. Test-negative design (TND) studies aim to include cases and controls from the same healthcare facilities; however, design choices or limitations associated with conducting real-world research can affect the study results. Here, we highlight how some methodological limitations may have affected results and conclusions of a published study described by Chandler et al.Keywords
Funding Information
- Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA
This publication has 13 references indexed in Scilit:
- Test-Negative DesignsEpidemiology, 2019
- Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Hospitalization for Community-Acquired Pneumonia in Older US Adults: A Test-Negative DesignClinical Infectious Diseases, 2018
- Theoretical Basis of the Test-Negative Study Design for Assessment of Influenza Vaccine EffectivenessAmerican Journal of Epidemiology, 2016
- Community-acquired pneumonia: An overviewPostgraduate Medicine, 2015
- Completeness and Accuracy of the Wisconsin Immunization RegistryJournal of Public Health Management & Practice, 2015
- Immunization Information Systems to Increase Vaccination RatesJournal of Public Health Management & Practice, 2015
- Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Recommendations of the Advisory Committee on Immunization Practices (ACIP)2014
- Antibody persistence ten years after first and second doses of 23-valent pneumococcal polysaccharide vaccine, and immunogenicity and safety of second and third doses in older adultsHuman Vaccines, 2011
- Repeat revaccination with 23-valent pneumococcal polysaccharide vaccine among adults aged 55–74 years living in Alaska: No evidence of hyporesponsiveness☆☆☆Vaccine, 2011
- Practice-based Electronic Billing Systems and Their Impact on Immunization RegistriesJournal of Public Health Management & Practice, 2005